Subscribe

Subscribe to our Newsletter and get informed about new publication regulary and special discounts for subscribers!

IJPPE > Volume 11 > In Silico Study on...
< Back to Volume

In Silico Study on N-Ferrocenylmethyl-N-Phenylpropionohydrazide and N-Ferrocenylmethyl-N-Pheylbenzohydrazide as Anticancer Drugs for Breast and Prostate Cancer

Full Text PDF

Abstract:

Molecular docking calculations were used to evaluate the antitumor activities of N-ferrocenylmethyl-N-phenylpropanamide (FP) and N-ferrocenylmethyl-N-pheylbenzohydrazide (FH) against the enzymes of breast cancer 17-beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) and human steroidogenic cytochrome P450 17A1 prostate cancer mutant A105L (CYP17A1). The molecular docking study was performed using the open source AutoDock 4.2 software. The obtained results showed that both FP and FH bind with 17β-HSD1 and CYP17A1 via hydrogen bonds, binding free energy values for the adducts FH-17β-HSD1 and FH-CYP17A1 were respectively equal to-27.67 and-27.55 KJmol-1, while for the adducts FP-17β-HSD1 and FP-CYP17A1 they were respectively equal to-29.13 and 29.18 KJmol-1. The negative values and the magnitude of the obtained binding free energy indicated respectively the spontaneity and the electrostatic interaction of both ligands FP and FH with 17β-HSD1 and CYP17A1 receptors as the dominant mode. Finally the ligand FP binds more strongly to the receptor CYP17A1 and forms two respective hydrogen bonds with Arg96 and His373; this finding clearly indicate that FP is best qualified as potential drug candidature for breast and prostate cancer.

Info:

Periodical:
International Journal of Pharmacology, Phytochemistry and Ethnomedicine (Volume 11)
Pages:
17-25
Citation:
Z. Nadjiba et al., "In Silico Study on N-Ferrocenylmethyl-N-Phenylpropionohydrazide and N-Ferrocenylmethyl-N-Pheylbenzohydrazide as Anticancer Drugs for Breast and Prostate Cancer", International Journal of Pharmacology, Phytochemistry and Ethnomedicine, Vol. 11, pp. 17-25, 2018
Online since:
October 2018
Export:
Distribution:
References:

[1] B.S. Hulka, A.T. Stark 1995 Breast cancer: cause and prevention, Lancet. 346 (1995) 883-887.

DOI: https://doi.org/10.1016/s0140-6736(95)92713-1

[2] C.J. Dhanaraj, J. Johnson, DNA interaction, antioxidant and in vitro cytotoxic activities of some mononuclear metal(II) complexes of a bishydrazone ligand, Materials Science and Engineering: C. 78 (2017) 1006-1015.

DOI: https://doi.org/10.1016/j.msec.2017.04.152

[3] C. Balmer, Prostate Cancer, in: R.A. Helms et al. (Eds.), Textbook of Therapeutics Drug and Disease Management, Eighth Edition, 2006, Philadelphia: Lippincott Williams and Wilkins, 2474.

[4] J.A. Aka et al., 17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production, Molecular Endocrinology. 24(4) (2010) 832-45.

DOI: https://doi.org/10.1210/me.2009-0468

[5] A.A Gilep, T.A. Sushko, S.A. Usanov, At the crossroads of steroid hormone biosynthesis: The role, substrate specificity and evolutionary development of CYP17, Biochimica et Biophysica Acta. 1814 (2010) 200-209.

DOI: https://doi.org/10.1016/j.bbapap.2010.06.021

[6] F.C. Mónica et al., Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency, Pharmaceuticals. 11 (2) (2018) 37-66.

DOI: https://doi.org/10.3390/ph11020037

[7] G.M. Morris et al., Software news and updates AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility, Journal of Computational Chemistry. 30(16) (2009) 2785–2791.

DOI: https://doi.org/10.1002/jcc.21256

[8] M.J. Frisch et aal.. Gaussian, Inc., Wallingford CT, (2009).

[9] H.M. Berman et al., The Protein Data Bank, Nucl. Acids Res. 28(1) (2000) 235-242.

[10] M. Mazumdar et al., Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy, Biochemical Journal 424 (2009) 357-366.

DOI: https://doi.org/10.1042/bj20091020

[11] E.M. Petrunak et al., Structures of Human Steroidogenic Cytochrome P450 17A1 with Substrates, Journal of Biological Chemistry. 289 (2014) 32952-32964.

DOI: https://doi.org/10.1074/jbc.m114.610998

[12] Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2017, San Diego: Dassault Systèmes, (2016).

[13] K.H. Darwin et al., The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science. 302 (2003) 1963-(1966).

DOI: https://doi.org/10.1126/science.1091176

[14] N. Bandyopadhyay et al., Synthesis, structure, DFT calculations, electrochemistry, fluorescence, DNA binding and molecular docking aspects of a novel oxime based ligand and its palladium (II) complex, J. Photochem. Photobiol B: Biology. 160 (2016).

DOI: https://doi.org/10.1016/j.jphotobiol.2016.04.026

[15] B. Guhathakurta et al., Synthesis, characterization, structure, DNA binding aspects and molecular docking study of a novel Schiff base ligand and its bis(µ-chloro) bridged Cu(II) dimer, Polyhedron. 126 (2017) 195-204.

DOI: https://doi.org/10.1016/j.poly.2017.01.033
Show More Hide
Cited By:
This article has no citations.